iShares US Medical Devices

ResMed and Oura Partner to Enhance Sleep Health Education and Care Pathways for US Members

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

Boston Scientific Announces Positive Results from SEISMIQ™ 4CE FRACTURE IDE Trial

FAMAR Group Signs Contract Manufacturing Agreement with GE HealthCare to Expand Iodine Contrast Agent Capacity

Stryker Agrees to Acquire Amplitude Vascular Systems for $835 Million

Boston Scientific Average Stock Price Target Cut to $83.8, Market Maintains Buy Consensus

Edwards Lifesciences EVP Donald E. Bobo Jr. Sells $1.47M in Shares

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Boston Scientific Signs $2 Billion Accelerated Share Repurchase Agreement

Boston Scientific Invests $1.5 Billion for 34% Stake in MiRus with Option to Acquire Balloon-Expandable TAVR System for $3 Billion

GEHC Receives 'Hold' Consensus from 17 Brokers, Executives Buy Shares to Show Confidence

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Stryker partners with Max Smart Hospital to advance surgical training for robotic-assisted joint replacements

NVision Completes $55 Million B Round Led by Abbott to Expand Quantum Computing Platform

Edward Lifesciences CEO Bernard J. Zallouk Sells Shares

Abbott Laboratories Sees Rising Dividend Yield Amid High Legal Costs and Infant Formula Litigation

GE HealthCare to Showcase AI-driven Radiotherapy Tools at ESTRO 2026

GE HealthCare Director Receives Restricted Stock Units and Buys Stocks

BD Medical applies for issuance of 600 million euros of notes

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

RenovoRx Earnings Call Signals Commercial Inflection

RNXT

ARKG

LABU

SBIO

RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.

Tip Ranks

RenovoRx

SPDR S&P Health Equip

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares US Pharma

ALPS Medical Breakthrough

iShares Biotechnology ETF

VG Health

Health Care Select Sector SPDR

VanEck Biotech ETF

Boston Scientific announced positive results from the FRACTURE trial for its SEISMIQ 4CE coronary IVL catheter, achieving primary safety and effectiveness goals in severe CAD patients. The trial showed a 93.3% freedom from major adverse cardiac events and a 93.7% procedural success rate. The device aims to improve stent placement by fracturing calcium buildup in arteries. Boston Scientific shares rose 2.27% to $57.19 following the announcement.

benzinga_article

Boston Scientific

S&P 500

Stellantis NV

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

AMIX

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Unusual Whales

Autonomix Medical

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

ISRG

ISUL

Resona Asset Management Co. Ltd. reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.1% in Q4, now holding 212,119 shares valued at $120.6 million. Other hedge funds, like Brighton Jones LLC and Main Street Financial Solutions LLC, increased their stakes. Insider sales included EVP Gary Loeb selling 400 shares and SVP Mark Brosius selling 2,362 shares. Intuitive Surgical's stock opened at $439.92, with a market cap of $155.8 billion and a recent earnings report showing a 23% revenue increase year-over-year.

Market Beat

Intuitive Surgical

GraniteShares 2x Long ISRG Daily ETF

Resona Holdings, Inc.

Truist Financial

Resona Asset Management Co. Ltd. Reduces Stock Holdings in Intuitive Surgical, Inc. $ISRG

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

West Pharmaceutical

Arcadian Asset

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

Stryker Corporation has acquired Amplitude Vascular Systems for up to $835 million to enhance its vascular treatment business. Amplitude developed a hydraulic intravascular lithotripsy platform for treating calcified peripheral arterial disease. The acquisition is seen as a strategic move to expand Stryker's offerings, including the Pulse System, which may provide improved treatment options. Stryker's stock is currently trading at $313.76, up 0.17%.

rttnews

Stryker

Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business

ORMP

Oramed Pharmaceuticals Inc. reported Q1 2026 results with $0 revenue and a net income of $38.31M, improving from a net loss of $(7.64) M in Q1 2025. Diluted EPS was $0.91, up from $(0.19) a year earlier. The company shifted to managing a medical technology portfolio, reduced R&D spending, and closed strategic transactions, including the Lifeward deal.

TradingView

Oramed Pharma

Lifeward

Alpha Tau Medical

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

Resona Asset Management Co. Ltd. reduced its stake in Danaher Corporation (NYSE:DHR) by 12.7% in Q4, now holding 448,050 shares valued at approximately $102.77 million. Other institutional investors have also adjusted their positions. Analysts have lowered price targets for Danaher, with a consensus rating of 'Moderate Buy' and a price target of $238.65. Danaher reported a quarterly EPS of $2.06, exceeding estimates, and announced a quarterly dividend of $0.40.

Danaher

Goldman Sachs

Wells Fargo

Johnson Controls

GS Hldg R

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints | BSX Stock News

StockTitan

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints | BSX Stock News

IRIX

IRIDEX CORP reported Q1 2026 revenue of $11.8M, a slight decrease from $11.9M a year ago, with a narrowed net loss of $0.52M compared to $1.69M previously. Diluted EPS improved to $(0.03) from $(0.10). Glaucoma sales rose 14.5%, while retina sales fell 12.3%. Management anticipates current cash will sustain operations for at least 12 months, focusing on cost savings and R&D discipline.

Iridex

Topcon Corp.

IRIDEX CORP 1Q 2026: Revenue $11.8M, EPS $(0.03) — 10-Q Summary

PAVM

Analyst Anthony Vendetti from Maxim Group has reaffirmed a Buy rating on PAVmed, maintaining a price target of $16. He cites the company's expanding oncology platforms, strategic partnerships, and the rollout of the Veris Cancer Care Platform as key factors. Vendetti highlights PAVmed's stake in Lucid Diagnostics and the momentum of EsoGuard testing, along with the relaunch of its medical device portfolio, as supporting elements for his rating.

PAVmed

Lucid Diagnostics

Icecure Medical

Daxor

PAVMED INC C/WTS 30/04/2025(TO PUR COM) CLASS Z

Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16

iShares US Medical Devices(IHI.US)

RenovoRx Earnings Call Signals Commercial Inflection

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Resona Asset Management Co. Ltd. Reduces Stock Holdings in Intuitive Surgical, Inc. $ISRG

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business

ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

Resona Asset Management Co. Ltd. Cuts Position in Danaher Corporation $DHR

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints | BSX Stock News

IRIDEX CORP 1Q 2026: Revenue $11.8M, EPS $(0.03) — 10-Q Summary

Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16